Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Veronica Ashton"'
Autor:
Michael Ingham, Hela Romdhani, Aarti Patel, Veronica Ashton, Gabrielle Caron-Lapointe, Anabelle Tardif-Samson, Patrick Lefebvre, Marie-Hélène Lafeuille
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 3, Pp 252-263 (2024)
This study assessed direct-acting oral anticoagulant (DOAC) switching/discontinuation patterns in patients with non-valvular atrial fibrillation (NVAF) in 2019, by quarter (Q1–Q4), and associated socioeconomic risk factors. Adults with NVAF initiat
Externí odkaz:
https://doaj.org/article/22ed7f3309ea488bb8257f304fd2c302
Publikováno v:
The Journal of Clinical Hypertension, Vol 26, Iss 5, Pp 500-513 (2024)
Abstract Apparent treatment‐resistant hypertension (aTRH), defined as blood pressure (BP) that remains uncontrolled despite unconfirmed concurrent treatment with three antihypertensives, is associated with an increased risk of developing cardiovasc
Externí odkaz:
https://doaj.org/article/b50e508a7ac244f285a042722e649099
Publikováno v:
The Journal of Clinical Hypertension, Vol 25, Iss 8, Pp 737-747 (2023)
Abstract Patients with apparent treatment‐resistant hypertension (aTRH) are at increased risk of end‐organ damage and cardiovascular events. Little is known about the effects of blood pressure (BP) control in this population. Using a national cla
Externí odkaz:
https://doaj.org/article/96bae165730146c18e52de0faef8dc5a
Autor:
Nitesh Sood, Veronica Ashton, Youssef Bessada, Katelyn Galli, Brahim K. Bookhart, Craig I. Coleman
Publikováno v:
TH Open, Vol 07, Iss 01, Pp e82-e93 (2023)
Background Obstructive sleep apnea (OSA) is associated with an increased incidence of atrial fibrillation (AF), hypertension, diabetes, heart failure, coronary heart disease, stroke, and death. We sought to evaluate the effectiveness and safety of ri
Externí odkaz:
https://doaj.org/article/4a1570d928144121bcbb5ca06d76bbfc
Autor:
Alex C. Spyropoulos, James M. Crawford, Yen-Wen Cindy Chen, Veronica Ashton, Alicia K. Campbell, Dejan Milentijevic, W. Frank Peacock
Publikováno v:
TH Open, Vol 06, Iss 04, Pp e408-e420 (2022)
Abstract Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some patients experience cardiovascular complications, including thromboembolic events and death. Data are needed to better inform prevention and treatment of these
Externí odkaz:
https://doaj.org/article/04918bee1c43480b9a82143a8f0c838c
Autor:
W. Frank Peacock MD, FACEP, FACC, FESC, James M. Crawford MD, PhD, Yen-Wen (Cindy) Chen PhD, Veronica Ashton MPH, Alicia K. Campbell PharmD, Dejan Milentijevic PhD, MBA, Alex C. Spyropoulos MD, FACP, FCCP, FRCPC
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)
Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021)
Externí odkaz:
https://doaj.org/article/e763408b7d534e61adeac7384af2b8bb
Autor:
Olivia S. Costa, Stanley Thompson, Veronica Ashton, Michael Palladino, Thomas J. Bunz, Craig I. Coleman
Publikováno v:
Thrombosis Journal, Vol 18, Iss 1, Pp 1-9 (2020)
Abstract Background African Americans are under-represented in trials evaluating oral anticoagulants for the treatment of acute venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban versus war
Externí odkaz:
https://doaj.org/article/e51d1e5c7f5d4f8bbe36ce907d2c77f3
Autor:
Olivia S. Costa PharmD, Jan Beyer-Westendorf MD, Veronica Ashton MPH, Dejan Milentijevic PhD, MBA, Kenneth Todd Moore MS, Thomas J. Bunz PharmD, PhD, Craig I. Coleman PharmD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
African Americans (AAs) and obese individuals have increased thrombotic risk. This study evaluated the effectiveness and safety of rivaroxaban versus warfarin in obese, AAs with nonvalvular atrial fibrillation (NVAF) or venous thromboembolism (VTE).
Externí odkaz:
https://doaj.org/article/1dacf04f817f4ecbae22ce1b2050b4fa
Publikováno v:
TH Open, Vol 04, Iss 04, Pp e344-e350 (2020)
Background Extended duration thromboprophylaxis (ET) for approximately 30 days can effectively and safely reduce venous thromboembolism (VTE) risk in appropriately selected medically ill patients. We sought to estimate the proportion of hospitalized
Externí odkaz:
https://doaj.org/article/126ac4b0617240dc98f62106017aabcd
Autor:
Anselm K. Gitt, Dominik Lautsch, Jean Ferrières, Gaetano M. De Ferrari, Ami Vyas, Carl A. Baxter, Lori D. Bash, Veronica Ashton, Martin Horack, Wael Almahmeed, Fu-Tien Chiang, Kian Keong Poh, Philippe Brudi, Baishali Ambegaonkar
Publikováno v:
Data in Brief, Vol 18, Iss , Pp 1937-1940 (2018)
DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 patients (93.8%) were on active lipid lowering therapy (LLT). The
Externí odkaz:
https://doaj.org/article/72b6ea01da3448e59793e75a6c86d0f7